Excited to report on the predictive value of anti-adenoviral antibodies from the Phase 3 nadofaragene firadenovec trial at #AUA21. 🔎 A novel therapeutic efficacy marker in BCG-unresponsive #NMIBC. 🙏🏽 a multicenter collaborative effort. Amer. Urol. Assn. MD Anderson Cancer Center

The nose and the trachea are the sites where #SARSCoV2 preferentially replicates, have the highest expression of the 2 key entry factors (ACE2 and TMPRSS2), as determined by extensive single-cell RNA-sequencing cell.com/cell-reports-m…

#SITC Award Recipients Congratulations Trent Gulley Dr James Gulley

Chemotherapy of an option for some #bladdercancer patients, but not all. In episode 15 of "Bladder Cancer Matters," host Rick Bangs talks with Guru P. Sonpavde, MD of Dana-Farber about what patients can do who who cannot receive chemo. Click here to listen: bcan.org/i-cant-get-che…

March is Kidney Cancer Awareness Month! KCCure KidneyCAN NationalKidneyFoundationSTL National Kidney Foundation Kidney Cancer

Burncoat High Drama Club will present "Lift Every Voice" in the METG regional competition next week and we will all be cheering them on.

🚨 JUST IN: Ivan Peršic has agreed terms on a two-year deal with #thfc. | Miguel Delaney independent.co.uk/sport/football…

#ChampionsLeagueFinalPing-Pong ball in the Liverpool end! Good call by the VAR!

Matt Turner first half highlights

Updated results from #CORE1 using pembro + cretostimogene (cg0070) in BCG unresponsive CIS 👉 Overall CR = 85% (29/34) 👉CR @ 12 months = 68% (17/25) 👉AE profile similar to monotherapy trials Gary Steinberg Ashish M. Kamat, MD, MBBS Trinity J. Bivalacqua CG Oncology, Inc. onclive.com/view/phase-2-d…

The opening salvo delivered by Mark Tyson

Excited to announce we have received both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive #BladderCancer Read the full release: businesswire.com/news/home/2023…

🏙 Heading to #ASCO24? Our #patientcentric approach addresses all stages of #bladdercancer w/innovative #immunotherapies. Hear the final results of our CORE-001 Phase 2 trial, showcasing our commitment to improving patient outcomes & transforming care. 🔗 bit.ly/3QZhf4T

Today at #ASCO24: In a phase 2 trial evaluating intravesical delivery of an oncolytic adenovirus + anti-PD-1 in patients with BCG unresponsive, non-muscle invasive #BladderCancer, the complete response rate at 12 months was 57.1% Roger Li doi.org/10.1038/s41591…

Great results from this combination! The best benefit (to risk) from systemic checkpoint inhibition I have seen yet for NMIBC

#ASCO24 CORE-001: Ph 2, single arm study of Creto + Pembro in BCG-UR, NMIBC w/ CIS Roger Li UroToday.com CG Oncology, Inc. ⚡️n=35 ⚡️CR rate 12 mo: 57.1% ⚡️CR rate 24 mo: 54.3% ⚡️CR rate any time: 82.9% ⚡️95.1% of CRs @ 12 mo remain in CR @ 24 mo ⚡️12 mo landmark RFS: 77.3% ⚡️24 mo

We're pleased to announce @CGOncology's Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. bit.ly/3Rv5a7C

There were ~83,000 new cases of #bladdercancer in the U.S. in 2024. Our investigational drug, cretostimogene grenadenorepvec, is designed to treat patients with BCG-unresponsive #NMIBC – which represents 75% of all new bladder cancer cases. Learn more: bit.ly/48IZnmi

Today Colin Dinney, MD, of MD Anderson Cancer Center shared some exclusive insights on updated data from the BOND-003 and CORE-001 trials of cretostimogene grenadenorepvec in BCG-unresponsive NMIBC! Check back at onclive.com to learn more! Amer. Urol. Assn. #AUA25 #blcsm